| Title： | Guidelines for Management of Children and Adolescents with COVID-19: An update |
| Edition： | Updated |
| Classification： | Standard guideline |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Pediatricians, clinical pharmacists, general practitioners, and nurses in the prevention and control of COVID-19 in children. |
| Evidence classification method： | We will use the GRADE system to rate the evidence. The evidence will be downgraded according to the following five criteria (risk of bias, inconsistency, indirectness, imprecision, and publication bias) or upgraded according to the following three criteria (large magnitude of the effect, dose-response, confounders likely minimize the effect). The final certainty of evidence will be graded as either high, moderate, low, or very low. |
| Development unit： | The China National Clinical Research Center for Children Health and Disease (Children’s Hospital of Chongqing Medical University); G-I-N Asia; Chinese GRADE Center; WHO Collaborating Centre for Guideline Implementation and Knowledge Translation |
| Registration time: | 2020-07-27 |
| Registration number： | IPGRP-2020CN101 |
| Purpose of the guideline: | Since the outbreak of COVID-19, it has become a life-threatening disease that poses a significant challenge to public health and health care systems worldwide. To ensure the timeliness and reliability of the guideline recommendations, the Working Group on Rapid advice guidelines for the management of children with COVID-19 initiated a process to update the guideline to provide practical guidance for the management of COVID-19 in children and adolescents in the post-epidemic era. |
Latest registration
